Clinical implications of thyrotropin receptor antibody measurement
10.3760/cma.j.issn.1000-6699.2011.04.029
- VernacularTitle:促甲状腺激素受体抗体检测的临床意义
- Author:
Yu YANG
;
Ang ZHENG
;
Chao LIU
;
Keying CAI
- Publication Type:Journal Article
- Keywords:
Thyrotropin;
Thyrotropin receptor antibody;
Graves'disease;
Methodology
- From:
Chinese Journal of Endocrinology and Metabolism
2011;27(4):360-364
- CountryChina
- Language:Chinese
-
Abstract:
It has been 50 years since the discovery of thyrotropin receptor autoantibody (TRAb). Advances in the knowledge of thyrotropin receptor ( TSHR) structure and function, combined with the elucidation of TSHR signaling and TSHR-autoantibody interaction have greatly facilitated our understanding of TRAb and their clinical applications. Measurement of TRAb activity plays an important role in the diagnosis of Graves' disease ( GD) and Graves' opthalmopathy. It has also been well recognized that TRAb is an effective predictor of GD relapse or remission after antithyroid drug and radioactive iodine treatment. TRAb test is of particular help in pregnant women and lactating mothers with recent iodine load, where radioactive iodine or technetium tests are contraindicated. In addition, it is useful in the diagnosis and differential diagnosis of fetal and neonatal hyperthyroidism as well as some rare forms of thyrotoxicosis in clinical practice. Accumulating evidence also indicates the possible correlation between thyroid cancer occurring in GD patients with positive TRAb and adverse outcomes. However, further innovation and standardization of TRAb tests are required to help pave the way for clinical applications.
